Form4insider filings, from the source

SEC Form 4 · accession 0001415889-18-001317

Vistagen Therapeutics, Inc. · VTGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Mark A. McPartland
Officer — VP CORPORATE DEVELOPMENT
Period of report
Aug 29, 2018
Accepted (ET)
Aug 31, 2018 · 5:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411685

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F1,F2$4.27Aug 29, 2018D125,000D—Sep 29, 2026Common Stock125,0000D
Stock Option (Right to Buy)F2$1.50Aug 29, 2018A125,000A—Sep 29, 2026Common Stock125,000125,000D
Stock Option (Right to Buy)F3,F4$3.80Aug 29, 2018D40,000D—Nov 9, 2026Common Stock40,0000D
Stock Option (Right to Buy)F4$1.50Aug 29, 2018A40,000A—Nov 9, 2026Common Stock40,00040,000D
Stock Option (Right to Buy)F5,F6$1.96Aug 29, 2018D100,000D—Apr 26, 2027Common Stock100,0000D
Stock Option (Right to Buy)F6$1.50Aug 29, 2018A100,000A—Apr 26, 2027Common Stock100,000250,000D

Explanation of responses